|Bid||11.89 x 900|
|Ask||19.00 x 800|
|Day's range||11.69 - 13.35|
|52-week range||11.69 - 22.24|
|Beta (5Y monthly)||1.53|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Spero's (SPRO) NDA for tebipenem HBr oral tablets for complicated urinary tract infections gets Priority Review.
Every investor in Spero Therapeutics, Inc. ( NASDAQ:SPRO ) should be aware of the most powerful shareholder groups...
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 0.00% and 2.13%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?